At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
CBL-514drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 2-Stage Adaptive Design, Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal and Thigh Subcutaneous Fat (Stage 1)
In Brief
A Phase 2 clinical trial evaluating CBL-514 for Subcutaneous Fat. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The Stage 1 of this phase 2 study is an open-label single ascending dose (SAD) study. The primary objectives are to evaluate the safety and tolerability of injection lipolysis with CBL-514. It will be followed by a parallel-arm multiple-dose design in Stage 2.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubcutaneous Fat
CountriesAustralia
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartDec 2020
Primary CompletionNov 2021
Study CompletionDec 2021
TodayJul 2026
First PostedOct 5, 2020
Enrollment StartDec 9, 2020
Primary CompletionNov 15, 2021
Study CompletionDec 8, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.7 years ago
Interventions
CBL-514drug
CBL-514 will be administered via injection into the subcutaneous adipose layer.